SCHEMBL6340344

SCHEMBL6340344

O=C(O)[C@H](Cc1ccc(O)c(O)c1)NCF

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM6B O15054 1/20 0.57
▸ KDM4E B2RXH2 4/20 0.55
▸ ALOX15 P16050 4/20 0.55
▸ HIF1A Q16665 4/20 0.55
▸ HSD17B10 Q99714 4/20 0.55
▸ RECQL P46063 3/20 0.55
▸ TDP1 Q9NUW8 3/20 0.55
▸ USP2 O75604 2/20 0.55
▸ ADORA3 P0DMS8 2/20 0.55
▸ HTR2A P28223 2/20 0.55
▸ PTGS2 P35354 2/20 0.55
▸ LCK P06239 2/20 0.55
▸ EGFR P00533 1/20 0.55
▸ FYN P06241 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ SLC7A5 Q01650 1/20 0.55
▸ CA1 P00915 3/20 0.52
▸ CA2 P00918 3/20 0.52
▸ MME P08473 2/20 0.50
▸ ACE P12821 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1718465 1.00 KDM6B (0.57) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL22364281 0.84 KDM6B (0.57) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL27315605 0.84 KDM4E (0.59) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL29700186 0.84 KDM6B (0.57) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL7433937 0.84 KDM6B (0.57) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL27285541 0.84 KDM4E (0.59) KDM6BKDM4EALOX15HIF1AHSD17B10
Hydrochloric Acid SCHEMBL10782448 0.84 KDM6B (0.61) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL3736877 0.84 KDM6B (0.60) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL30915529 0.84 KDM6B (0.60) KDM6BKDM4EALOX15HIF1AHSD17B10
SCHEMBL29577557 0.84 KDM6B (0.60) KDM6BKDM4EALOX15HIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 — — US claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 — — US disclosed
US-6555663-B1 Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule MILLS RANDELL LEE (US) 2003-04-29 — — US disclosed
EP-0414730-B1 Chemical Compounds and pharmaceutical compositions capable of releasing a drug MILLS RANDELL L (US) 1999-12-15 — — EP disclosed
US-5773592-A COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED MILLS RANDELL LEE (US) 1998-06-30 — — US disclosed
US-5428163-A Luminides; chemiluminescence; redox system, releasing free drug MILLS RANDELL L (US) 1995-06-27 — — US disclosed
EP-0414730-A4 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS — 1993-06-16 — — EP disclosed
EP-0414730-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS Mills, Randell L. (US) 1991-03-06 — — EP disclosed
WO-1989009833-A1 LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS MILLS RANDELL L (US) 1989-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD KDM6B 2263/4885KDM4E 3072/4885ALOX15 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback